Andrea Necchi, MD

Videos

Intravesical Gemcitabine Delivery System, TAR-200, Shows Promise Among Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

11/03/2023

Andrea Necchi , MD;

Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.

Andrea Necchi, MD, describes the...

11/03/2023

Oncology

Conference Coverage

TAR-200 Plus Cetrelimab Provides Promising Clinical Benefit for Patients With Muscle-Invasive Bladder Cancer

10/23/2024

Andrea Necchi , MD;

Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...

Andrea Necchi, MD, discusses...

10/23/2024

Oncology